Intra-Cellular Therapies logo

Intra-Cellular TherapiesNASDAQ: ITCI

Profile

Sector:

Healthcare

Country:

United States

IPO:

07 January 2014

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$9.36 B
-3%vs. 3y high
92%vs. sector
-vs. 3y high
-vs. sector
-41%vs. 3y high
90%vs. sector
-78%vs. 3y high
83%vs. sector

Price

pre-market | 32 min ago
$88.29+$2.29(+2.66%)

Dividend

No data over the past 3 years
$175.16 M$194.02 M
$175.16 M-$26.32 M

Analysts recommendations

Institutional Ownership

ITCI Latest News

Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
seekingalpha.com30 October 2024 Sentiment: NEUTRAL

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman and CEO Mark Neumann - EVP and CCO Sanjeev Narula - CFO Suresh Durgam - EVP and CMO Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Charles Duncan - Cantor Jason Gerberry - Bank of America Securities Jeff Hung - Morgan Stanley Michael DiFiore - Evercore David Amsellem - Piper Sandler Joel Beatty - Baird Corinne Johnson - Goldman Sachs Operator Good day and thank you for standing by. Welcome to Intra-Cellular Therapies 3Q 2024 Earnings Conference Call.

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
globenewswire.com30 October 2024 Sentiment: POSITIVE

CAPLYTA Q3 2024 net product sales were   $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase

ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
zacks.com30 October 2024 Sentiment: POSITIVE

Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
zacks.com23 October 2024 Sentiment: POSITIVE

Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
zacks.com11 October 2024 Sentiment: POSITIVE

ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
globenewswire.com23 September 2024 Sentiment: POSITIVE

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
zacks.com06 September 2024 Sentiment: NEUTRAL

Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
globenewswire.com28 August 2024 Sentiment: POSITIVE

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:

Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon
investors.com08 August 2024 Sentiment: POSITIVE

This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming.

Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
zacks.com08 August 2024 Sentiment: POSITIVE

Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

  • 1(current)
  • 2

What type of business is Intra-Cellular Therapies?

Intra-Cellular Therapies, Inc. is an American biopharmaceutical company. It has been in operation since 2001 and was officially registered in 2013 in the state of Delaware. The headquarters are located in New York. The company focuses on the development of small molecule drugs for the treatment of neuropsychiatric and neurological disorders. The drug candidate CAPLYTA has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults and is currently entering the commercialization phase. The drug candidate Lumateperone is intended for the treatment of depression associated with bipolar disorders, as well as for the treatment of agitation in patients with dementia, including Alzheimer's disease.

What sector is Intra-Cellular Therapies in?

Intra-Cellular Therapies is in the Healthcare sector

What industry is Intra-Cellular Therapies in?

Intra-Cellular Therapies is in the Drug Manufacturers - Specialty & Generic industry

What country is Intra-Cellular Therapies from?

Intra-Cellular Therapies is headquartered in United States

When did Intra-Cellular Therapies go public?

Intra-Cellular Therapies initial public offering (IPO) was on 07 January 2014

What is Intra-Cellular Therapies website?

https://www.intracellulartherapies.com

Is Intra-Cellular Therapies in the S&P 500?

No, Intra-Cellular Therapies is not included in the S&P 500 index

Is Intra-Cellular Therapies in the NASDAQ 100?

No, Intra-Cellular Therapies is not included in the NASDAQ 100 index

Is Intra-Cellular Therapies in the Dow Jones?

No, Intra-Cellular Therapies is not included in the Dow Jones index

When was Intra-Cellular Therapies the previous earnings report?

No data

When does Intra-Cellular Therapies earnings report?

The next expected earnings date for Intra-Cellular Therapies is 21 February 2025